Pharmalittle: AstraZeneca reports trial setback, U.S. drug prices fall
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating…
Pharmalittle: AstraZeneca reports trial setback, U.S. drug prices fall
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating…
STAT Health Tech: Are AI scribes medical devices? UK regulator weighs in
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech;…
Pharmalittle: AstraZeneca, Bristol talking merger, 340B plan revised
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating…
Pharmalittle: FDA critical of Duchenne drug, GSK seeks savings
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our…
GSK lays out plans to cut costs, pursue more late-stage drug trials
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
Pharmalittle: Drug shortages rise, GSK cough medicine trials fail
And so, another working week will soon draw to a close. Not a moment too soon, yes? This…
AstraZeneca, Ionis report major trial failure with heart disease drug
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
Pharmalittle: Vera kidney drug approved, U.K. nears Enhertu deal
Good morning, Jason Mast here filling in for the one and only Ed Silverman. We’re here in STAT’s…
Pharmalittle: Vera kidney drug approved, U.K. nears Enhertu deal
Good morning, Jason Mast here filling in for the one and only Ed Silverman. We’re here in STAT’s…
AstraZeneca to pay $34M to settle kickback charges filed by Texas AG
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Pharmalittle: GSK agrees to buy Nuvalent cancer drug developer
Rise and shine, everyone, another busy day is on the way. And it is getting off to a…